An innovative Chinese Alzheimer's drug that hit the domestic market last week, will go through clinical trials on 2,000 patients overseas in 2020.

The orally administered drug GV-971 will be tested in 200 clinical centers in North America, the European Union, Eastern Europe, Asia Pacific and other places, according to Green Valley Pharmaceutical Co., Ltd, one of the drug's co-developers.

The company says it plans to complete the global clinical trials in 2024 and submit the New Drug Application to the U.S. Food and Drug Administration and European Medicines Agency in 2025.

GV-971 was jointly developed by the Ocean University of China, Shanghai Institute of Materia Medica under the Chinese Academy of Sciences (CAS) and Green Valley, after a 22-year study.

The results of the mechanism of action study were published in the international journal Cell Research in September 2019, saying that the drug, extracted from brown algae, works by modifying gut bacteria to ultimately reduce brain inflammation in mice that were genetically engineered to have the disease. (Xinhua)

Original linker: http://www.xinhuanet.com/english/2020-01/04/c_138678444.htm?from=groupmessage

(Editor: WANG xiaocheng)